Frazier Life Sciences Management’s Cerevel Therapeutics Holdings CERE Stock Holding History
Bought
Maintained
Sold
Other funds holding CERE
Frazier Life Sciences Management's CERE Position: Q3 2024 in Review
Frazier Life Sciences Management sold out of Cerevel Therapeutics Holdings (CERE) in Q3 2024, closing a stake of 393,000 shares — an estimated $16.1M sold.
Frazier Life Sciences Management first reported a position in CERE in Q1 2022 and held it in 10 quarters. The position peaked at $16.7M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.
- Frazier Life Sciences Management reported no remaining Cerevel Therapeutics Holdings position as of Q3 2024 after selling out during the quarter.
- Frazier Life Sciences Management sold 393,000 Cerevel Therapeutics Holdings shares in Q3 2024, an estimated $16.1M.
- Frazier Life Sciences Management first reported a position in Cerevel Therapeutics Holdings in Q1 2022 and held it in 10 quarters.
- Frazier Life Sciences Management's Cerevel Therapeutics Holdings position peaked at $16.7M in Q4 2023.
- 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings as of Q3 2024.
Based on Frazier Life Sciences Management's 13F filing for Q3 2024, filed 15 Nov 2024.